Teva Pharmaceutical Industries Ltd. — Regulatory Filings 2017

Oct 10, 2017

6-K 1 htm_11591.htm LIVE FILING HTML Header Page Teva Pharmaceutical Industries Ltd. - Form 6-K End HTML Header Page Cover Page Header

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October, 2017

Commission File Number: 001-16174 End Cover Page Header Cover Page Registrant

Teva Pharmaceutical Industries Ltd. ———————————————————————————————————
(Translation of registrant’s name into English)
Israel ———————————————————————————————————
(Jurisdiction of incorporation or organization)
5 Basel Street, P.O. Box 3190 Petach Tikva 4951033 Israel
——————————————————————————————————— (Address of principal executive office)

End Cover Page Registrant Checkboxes Page

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: [ x ] Form 20-F [ ] Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ]
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: [ ] Yes [ x ] No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): n/a

End Checkboxes Page HR Page Break

End HR Page Break Report Page End Report Page Page Break

Page Break

End Page Break Signatures Page Header SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

End Signatures Page Header Signatures Page Details

By:	Teva Pharmaceutical Industries Ltd. — Michael McClellan
Name:	Michael McClellan
Title:	Interim Chief Financial Officer

End Signatures Page Details HR Page Break

End HR Page Break Exhibit Index Header Page EXHIBIT INDEX

Exhibit No.	Description
99.1	Teva to Report Third Quarter 2017 Financial Results on November 2, 2017

End ExhibitIndexFooter HR Page Break

End HR Page Break HTML Footer Page End HTML Footer Page